| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $14,031 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Thompson Tommy G | director | 1 | $14,031 | 0 | $0 | $14,031 |
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; …
Over the last 12 months, insiders at TherapeuticsMD, Inc. have bought $14,031 and sold $0 worth of TherapeuticsMD, Inc. stock.
On average, over the past 5 years, insiders at TherapeuticsMD, Inc. have bought $5.45M and sold $12.93M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Thompson Tommy G (director) — $14,031.
The last purchase of 8,400 shares for transaction amount of $14,031 was made by Thompson Tommy G (director) on 2025‑12‑23.
| 2025-12-23 | Thompson Tommy G | director | 8,400 0.0722% | $1.67 | $14,031 | +26.83% | ||
| 2025-04-14 | Walker Marlan D | Chief Executive Officer | 490 0.0047% | $1.00 | $489 | +34.95% | ||
| 2025-04-14 | Thompson Tommy G | director | 325 0.0031% | $1.00 | $326 | +34.95% | ||
| 2025-04-10 | Walker Marlan D | Chief Executive Officer | 1,167 0.0096% | $0.86 | $1,000 | +55.82% | ||
| 2025-04-09 | Walker Marlan D | Chief Executive Officer | 1,136 0.0095% | $0.87 | $994 | +49.44% | ||
| 2024-08-22 | Collins Cooper C. | director | 4,094 0.0352% | $1.73 | $7,099 | -33.14% | ||
| 2024-08-21 | Collins Cooper C. | director | 1,200 0.0105% | $1.70 | $2,039 | -30.77% | ||
| 2023-12-07 | Sale | Walker Marlan D | Chief Executive Officer | 4,550 0.0421% | $2.24 | $10,187 | -14.48% | |
| 2023-12-06 | Sale | Walker Marlan D | Chief Executive Officer | 14,500 0.1412% | $2.31 | $33,496 | -16.00% | |
| 2023-04-26 | Sale | Walker Marlan D | Chief Executive Officer | 692 0.0079% | $3.64 | $2,518 | -25.78% | |
| 2023-04-12 | Sale | Walker Marlan D | Chief Executive Officer | 1,170 0.013% | $3.65 | $4,276 | -23.14% | |
| 2023-01-27 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 49 0.0005% | $5.09 | $249 | -30.90% | |
| 2023-01-26 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 1,648 0.0183% | $5.08 | $8,371 | -27.36% | |
| 2023-01-24 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 7 <0.0001% | $5.31 | $37 | -29.39% | |
| 2023-01-23 | Sale | Donegan Michael C | Prin. Fin. and Acctg. Officer | 1,302 0.0145% | $5.34 | $6,950 | -30.45% | |
| 2022-12-30 | Sale | Rubric Capital Management LP | director | 29,000 – | $1,333.00 | $38.66M | -31.75% | |
| 2022-12-09 | Sale | Bernick Brian | Co-Chief Executive Officer | 320 0.0035% | $6.31 | $2,020 | -39.64% | |
| 2022-12-09 | Rubric Capital Management LP | director | 14,825 0.1558% | $6.09 | $90,284 | -39.64% | ||
| 2022-12-08 | Rubric Capital Management LP | director | 300 0.0032% | $5.83 | $1,749 | -35.12% | ||
| 2022-12-07 | Sale | Naughton Gail K | director | 3,922 0.038% | $5.26 | $20,635 | -35.44% |
| Thompson Tommy G | director | 23179 0.2003% | $41,258.62 | 15 | 0 | +3.79% |
| Finizio Robert G | CEO | 17991637 155.4439% | $32.03M | 5 | 24 | <0.0001% |
| Milligan John C.K. IV | Secretary/CEO of subsidiary | 1752703 15.143% | $3.12M | 3 | 24 | <0.0001% |
| C.S. Finance LLC | 357606 3.0896% | $636,538.68 | 1 | 0 | ||
| JENSEN GERALD L | President | 258878 2.2367% | $460,802.84 | 26 | 0 | |
| SEGAL NICHOLAS | director | 215485 1.8617% | $383,563.30 | 1 | 1 | +111.31% |
| BISARO PAUL | director | 196864 1.7009% | $350,417.92 | 2 | 0 | +22.32% |
| Ling Karen | director | 130309 1.1258% | $231,950.02 | 1 | 0 | |
| Russell Angus C. | director | 93500 0.8078% | $166,430.00 | 5 | 0 | <0.0001% |
| Walker Marlan D | Chief Executive Officer | 73639 0.6362% | $131,077.42 | 3 | 6 | +46.74% |
| Collins Cooper C. | director | 52016 0.4494% | $92,588.48 | 9 | 1 | <0.0001% |
| Rosen David Efraim | 22000 0.1901% | $39,160.00 | 3 | 0 | <0.0001% | |
| MANDEL RICHARD H JR | director | 13100 0.1132% | $23,318.00 | 4 | 2 | |
| CARROLL J MARTIN | director | 10000 0.0864% | $17,800.00 | 1 | 0 | +16.97% |
| LaPenta Robert V Jr | director | 10000 0.0864% | $17,800.00 | 1 | 0 | +22.11% |
| MUSING JULES A. | director | 5000 0.0432% | $8,900.00 | 2 | 1 | +112.05% |
| Bernick Brian | Co-Chief Executive Officer | 3872 0.0335% | $6,892.16 | 2 | 24 | <0.0001% |
| Barlow Jane F | director | 3144 0.0272% | $5,596.32 | 1 | 0 | <0.0001% |
| Rubric Capital Management LP | director | 0 0% | $0 | 4 | 1 | <0.0001% |
$2,101,005 | 2135 | -11.51% | $64.58M | |
$131,310,609 | 62 | 26.99% | $107.44M | |
$2,767,882 | 51 | 8.70% | $24.78M | |
TherapeuticsMD, Inc. (TXMD) | $30,221,759 | 51 | 0.50% | $20.6M |
$33,884,330 | 45 | 12.56% | $223.45M |
| Increased Positions | 11 | +21.15% | 134,413 | +4.07% |
| Decreased Positions | 13 | -25% | 53,312 | -1.61% |
| New Positions | 4 | New | 37,381 | New |
| Sold Out Positions | 6 | Sold Out | 25,610 | Sold Out |
| Total Postitions | 50 | -3.85% | 3M | +2.45% |
| Rubric Capital Management Lp | $1,967.00 | 9.94% | 1.19M | 0 | 0% | 2025-09-30 |
| Clearline Capital Lp | $1,048.00 | 5.29% | 635,222 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $622.00 | 3.14% | 376,828 | -2,173 | -0.57% | 2025-09-30 |
| Tejara Capital Ltd | $568.00 | 2.87% | 344,203 | -51 | -0.01% | 2025-09-30 |
| Adar1 Capital Management, Llc | $345.00 | 1.74% | 209,210 | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $215.00 | 1.09% | 130,572 | -638 | -0.49% | 2025-09-30 |
| Blackrock, Inc. | $192.00 | 0.97% | 116,132 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $180.00 | 0.91% | 109,083 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $59.00 | 0.3% | 35,500 | +20,600 | +138.25% | 2025-09-30 |
| Citadel Advisors Llc | $57.00 | 0.29% | 34,273 | +34,273 | New | 2025-09-30 |